The India-UK free trade agreement safeguards the domestic generic drug industry. It avoids patent term extensions and data exclusivity. This prevents evergreening of patents. Indian patent law remains protected. The agreement, signed on July 24, will be effective in a year. India previously rejected similar demands from EFTA. The move ensures affordable medicines.